Latest Product Launches News

First Graphene has launched its PureGRAPH-enhanced waterproofing additive in South Africa, marking a significant step into the regional cement and concrete sector with promising trial results and initial commercial orders.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.

The Calmer Co International Limited has reported its strongest quarterly revenue ever at $2.4 million, driven by robust Australian retail sales and expanding US market presence. The company is also advancing a $1.4 million convertible note to fuel growth and inventory expansion.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.

The Calmer Co. has secured $700,000 in the first tranche of a $1.4 million convertible note raise, welcoming US distributor Applied Food Sciences as a strategic investor to fuel its expanding wholesale presence.

Premier Investments reported a 31.1% rise in net profit after tax for FY25, driven by strong growth in its continuing operations after divesting its Apparel Brands to Myer. The company is now concentrating on expanding its high-margin Peter Alexander and Smiggle brands.

Atomos Limited has expanded its secured debt facility by $2 million, increasing its total borrowing capacity to $15.7 million, signaling confidence in its strategic turnaround and upcoming product launches.

Clover Corp has reported a standout FY25 with robust revenue and profit growth, driven by new product launches and strategic investments that strengthen its global supply chain and market reach.

ReNerve Limited has launched its Empliq tissue product range in the US, marking a strategic expansion into the growing dermal and amniotic tissue market. The launch complements its existing nerve repair portfolio and sets the stage for further growth.

Race Oncology has uncovered that its anticancer drug bisantrene exists as three light-sensitive isomers, with only one showing potent activity. The company has filed patents to protect this active form, potentially extending its intellectual property rights until 2045.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

OMG Group has significantly expanded its Oat Milk Goodness PrOATein ready-to-drink range to nearly 1,000 Woolworths stores nationwide, backed by a recent $2 million capital raise and plans for new product launches.